Thyroid carcinoma (TC) is rare and represents 1-2 % of all human tumors. The incidence of TC has been increasing worldwide. TC comprises of a heterogeneous group of tumours with variable biological activity. Women are mostly affected. TC can be divided in differentiated TC/DTCs (papillary - PTC, follicular - FTC, from Hürthle cells - HCC), medullary carcinoma - MTC and anaplastic thyroid cancer - ATC. In this article, we focus on possible pitfalls of suppression therapy (cardiovascular, bone and mental), particularly in low-risk patients, and we discuss the data on the adherence to guidelines for suppression therapy in DTC.
Keyphrases
- patient reported
- endothelial cells
- clinical practice
- mental health
- type diabetes
- squamous cell carcinoma
- stem cells
- bone mineral density
- oxidative stress
- pregnant women
- ejection fraction
- risk factors
- cell death
- papillary thyroid
- cell therapy
- body composition
- metabolic syndrome
- risk assessment
- cell cycle arrest
- end stage renal disease
- bone marrow
- human health
- skeletal muscle
- newly diagnosed
- induced pluripotent stem cells
- replacement therapy
- lymph node metastasis
- deep learning